Pralsetinib

Last Updated: 11/08/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 302 publications

Precision Thyroid Oncology Using Genetic-Based Therapies: A Narrative Review.

Precision Thyroid Oncology Using Genetic-Based Therapies: A Narrative Review.

Journal: Thyroid : official journal of the American Thyroid Association
Published: October 20, 2026

Case Report: Discordance between RNA-identified ETV6::RET and clinically reportable DNA profiling in salivary gland secretory carcinoma.

Case Report: Discordance between RNA-identified ETV6::RET and clinically reportable DNA profiling in salivary gland secretory carcinoma.

Journal: Frontiers in oncology
Published: August 14, 2026

Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC.

Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 27, 2026

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.

Journal: Frontiers in oncology
Published: July 16, 2026

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Journal: Thyroid : official journal of the American Thyroid Association
Published: June 24, 2026

Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a "chemical adaptation" strategy.

Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a "chemical adaptation" strategy.

Journal: Bioorganic chemistry
Published: June 16, 2026

Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)

Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: May 20, 2026

Molecular clusters and precision medicine in pheochromocytomas and paragangliomas.

Molecular clusters and precision medicine in pheochromocytomas and paragangliomas.

Journal: Endocrine-related cancer
Published: May 19, 2026

Pralsetinib-induced interstitial pneumonitis in a patient with metastatic pulmonary sarcomatoid carcinoma harboring RET fusion: a case report.

Pralsetinib-induced interstitial pneumonitis in a patient with metastatic pulmonary sarcomatoid carcinoma harboring RET fusion: a case report.

Journal: AME case reports
Published: May 18, 2026

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

Journal: Pharmacological research
Published: May 05, 2026

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.

Journal: Investigational new drugs
Published: May 05, 2026

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine.

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine.

Journal: Drugs in context
Published: April 14, 2026
Showing 1-12 of 302

Last Updated: 11/08/2026